Number of shares and voting rights of Innate Pharma as of May 1, 2021
MARSEILLE, France, May 25, 2021 (GLOBE NEWSWIRE) – Pursuant to article L. 233-8 II of the Commercial Code and article 223-16 of the French stock exchange authorities (Financial Markets Authority, or “AMF“) General Regulations, Innate Pharma SA (the”Company“- Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) publishes its total number of outstanding shares and voting rights as of May 1, 2021:
Total number of shares outstanding:
78,997,540 ordinary shares
6,796 preferred shares 2016
7,581 preferred shares 2017
Total number of theoretical voting rights (1):
Total number of exercisable voting rights (2):
79 773 465
(1) The total number of theoretical voting rights (or âgrossâ voting rights) is used as the basis for calculating the crossing of the holding thresholds. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which voting rights are attached, including the shares whose voting rights have been suspended. The total number of theoretical voting rights includes the voting rights attached to AGAP 2016 (Preferred Shares 2016), i.e. 130 voting rights for AGAP 2016-1 and 111 voting rights for AGAP 2016-2 .
(2) The total number of exercisable voting rights (or ânetâ voting rights) is calculated without taking into account the shares held directly by the Company, with voting rights suspended. It is distributed in such a way as to ensure adequate market information, in accordance with the AMF recommendation of July 17, 2007.
About Innate Pharma:
Innate Pharma SA is a global clinical-stage oncology-focused biotechnology company dedicated to improving treatments and patient outcomes through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s extensive antibody portfolio includes several potentially first-rate clinical and preclinical candidates in cancers with high unmet medical needs.
Innate has been a pioneer in understanding the biology of natural killer cells and has broadened its expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. This innovative approach has resulted in a diverse proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A / S, Sanofi, and a multi-product collaboration with AstraZeneca.
Based in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and on Nasdaq in the United States.
Learn more about Innate Pharma on: www.innate-pharma.com
Information on Innate Pharma’s actions:
Stock exchange code
Euronext: IPH Nasdaq: IPHA
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including âbelieveâ, âpotentialâ, âexpectâ and âwillâ and similar expressions, is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including related to the safety, progress and results of its ongoing and planned clinical trials and preclinical studies, review and regulatory approvals of its product candidates, the company’s marketing efforts, the company’s continued ability to raise capital to finance its development, and the overall impact of the COVID-19 outbreak on the system. global health and the Company’s business, financial condition and results of operations. For further discussion of the risks and uncertainties that could cause the Company’s actual results, financial position, performance or achievements to differ from those contained in forward-looking statements, please refer to the Risk Factors section (â Risk factors â) of the Universal Registration Document filed with the AutoritÃ© des MarchÃ©s Financiers (â AMF â), available on the AMF website http://www.amf-france.org or on the website Innate Pharma’s Internet, and public filings and reports filed with the US Securities and Exchange Commission (âSECâ), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020, as well as subsequent filings and reports filed with the AMF or the SEC or made public by the Company.
This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares of Innate Pharma in any country.